Open AccessPharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice
Author(s) -
П. А. Балунов,
А Н Хитров
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-21-96-104
Subject(s) - copd , pulmonary disease , medicine , intensive care medicine , disease , pharmacoeconomics , drug , unit (ring theory) , pharmacology , mathematics education , mathematics
Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia. The prevalence and high mortality of this disease lead to a significant socio-economic burden. A pharmacoeconomic comparison of two alternative drug technologies in the studied groups grants the reasonable opportunity to transfer patients to the domestic analogues, confirming that efficiency unit costs for using Tiotropium-native and Ipraterol-native are lower than the same costs for using the foreign drugs Spiriva and Berodual.